^
    6d
    EVOLVE-BDT: Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (clinicaltrials.gov)
    P2, N=700, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial
    |
    Tempus xR
    |
    everolimus • capecitabine • Verzenio (abemaciclib)
    6d
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Suspended, University of Southern California | Recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    6d
    A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer. (clinicaltrials.gov)
    P1, N=15, Recruiting, Xiaorong Sun
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 expression • ER negative
    7d
    CAPItrue: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (clinicaltrials.gov)
    P3, N=300, Recruiting, AstraZeneca | N=560 --> 300
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD4 (CD4 Molecule)
    |
    HER-2 negative • PGR positive
    |
    fulvestrant • Truqap (capivasertib)
    7d
    The miRNA-4330/ABCG2 axis overcomes drug resistance and cancer progression in both ER-positive and ER-negative resistant breast cancer cells. (PubMed, Clin Transl Oncol)
    The current findings identified miR-4330 restoration as a tool for overcoming acquired drug resistance and reducing cancer activity, which might be used to improve therapeutic strategies and treatment regimens for breast cancer patients. miR-4330 may be useful as a diagnostic and prognostic marker for drug-resistant breast cancer.
    Journal
    |
    ER (Estrogen receptor) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • MIR433 (MicroRNA 433)
    |
    ER positive • ER negative
    |
    doxorubicin hydrochloride
    7d
    neoMono: Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (clinicaltrials.gov)
    P2, N=442, Terminated, Palleos Healthcare GmbH | Completed --> Terminated; The trial stopped recruitment prematurely after a first planned interim analysis of the first 100 pCR results (given that a probability of less than 2.5% of meeting the primary endpoint was estimated).
    Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • ER negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    8d
    ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC (clinicaltrials.gov)
    P1/2, N=78, Active, not recruiting, Filipa Lynce, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • azenosertib (ZN-c3)
    11d
    ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, Laura Huppert, MD, BA | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HR negative
    |
    anvatabart opadotin (JNJ-0683)
    11d
    IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov)
    P1/2, N=29, Suspended, University of Florida | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HR negative + HER-2 positive
    |
    Tecentriq (atezolizumab) • Fotivda (tivozanib)
    13d
    CROWN: Cardiac Outcomes With Near-Complete Estrogen Deprivation (clinicaltrials.gov)
    P=N/A, N=90, Recruiting, Duke University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HR positive • HER-2 negative
    14d
    Prognosis and endocrine therapy efficacy in early breast cancer with estrogen receptor low expression. (PubMed, Breast Cancer Res Treat)
    HER2-negative/ER-low breast cancer has a similar clinical behavior to triple-negative breast cancer, and ET could significantly reduce the risk of recurrence and metastasis for this subgroup. However, in HER2-positive patients, ER-low breast cancer lacks a predictive role in prognosis and derives no clear benefit from ET.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • HER-2 negative • ER negative • HER-2 negative + ER positive
    15d
    TNBC-RT2023: Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=15, Active, not recruiting, Centre Paul Strauss | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Aug 2030 | Trial primary completion date: Apr 2027 --> Oct 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative